March 14th 2025
Carfilzomib, lenalidomide, and dexamethasone results from the real world continued to show effective responses and a tolerable safety profile.
Medical Crossfire®: Real World Strategies to Improve Therapeutic Durability and Outcomes in CLL
February 20, 2025
Register Now!
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Considering NCCN Guidelines to Determine Maintenance Therapy Multiple Myeloma
February 15th 2025During the 66th American Society of Hematology Annual Meeting and Exposition, experts in multiple myeloma gathered to discuss the impact of maintenance therapy and minimal residual disease (MRD) in patients with newly diagnosed transplant-eligible or -ineligible multiple myeloma.
CAR T-Cell Therapy in Multiple Myeloma: Lessons Learned and Key Takeaways
January 31st 2025Panelists discuss how UCSF Health has learned that successful integration of CAR T-cell therapy in multiple myeloma requires multidisciplinary collaboration, patient selection optimization, and management of toxicities. Future research includes exploring CAR T-cell therapy in earlier treatment lines and combining it with novel agents to enhance efficacy.
Example of Successful Collaboration with a Referring Community Practice
January 31st 2025Panelists discuss collaborating with community practices on CAR T-cell therapy for multiple myeloma through joint clinical trials, patient education programs, and shared data initiatives. These partnerships enhance treatment access, foster innovation, and improve patient outcomes across diverse settings.
Key Takeaways in CAR-T Therapy for Multiple Myeloma
January 20th 2025Panelists discuss a clinical scenario involving a 56-year-old male man with myeloma and del 17p deletion, treated with RVD induction, auto transplant, and lenalidomide maintenance, who relapsed after 2 years and is now referred to discuss chimeric antigen receptor (CAR) CAR-T versus vs standard therapy, sharing key takeaways and pearls from the case.